CBX2

Across TCGA pan-cancer cohorts, CBX2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CBX2 data layer compared with 31 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CBX2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CBX2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where CBX2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.770	0.286	.013	5	view →
HNSC	OS	Median	All	0.452	1.000	.025	5	view →
LSCC	DFS	Median	All	0.972	0.905	.028	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CBX2–PDAC (OS)

Open the PDAC breakdown →